Full Press Release Details
ADVISORY, Sept. 5, 2012 (GLOBE NEWSWIRE) --
Galectin Therapeutics Inc., a pharmaceutical company, will visit the NASDAQ MarketSite in Times Square to celebrate its Initial Public Offering in March of 2012.
In honor of the occasion, Dr. Peter Traber, President and CEO, will ring the Closing Bell.
NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio
Thursday, September 6th, 2012 - 3:45 p.m. to 4:00 p.m. ET
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Galectin Therapeutics, Inc.:
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com. Reuters News Service recently reported GALT stock soared after a patent announcement and jumped on analyst's report.